Charles River EVP exercises and sells 4,179 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Charles River Laboratories International, Inc. reported that EVP & Chief People Officer Victoria L. Creamer exercised stock options for 4,179 shares of common stock on 2026-08-06 at an exercise price of $179.66 per share and immediately sold 4,179 shares of common stock at $259.16 per share. The exercised options covered 4,179 shares and now show 0 derivative shares remaining from this grant.
Insider Trade Summary
Exercise and Sale: 4,179 shares ($332K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Creamer Victoria L
Role
EVP & Chief People Officer
Sold
4,179 shs ($1.08M)
Approx. gross sale proceeds
$1.08M
Approx. exercise cost
$751K
Approx. pre-tax spread
$332K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) | 4,179 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,179 | $179.66 | $751K |
| Sale | Common Stock | 4,179 | $259.16 | $1.08M |
Holdings After Transaction:
Stock Options (Right to Buy) — 0 contracts (Direct);
Common Stock — 30,051 shares (Direct)
Key Figures
Options exercised: 4,179 shares
Option exercise price: $179.66 per share
Shares sold: 4,179 shares
+3 more
6 metrics
Options exercised
4,179 shares
Stock options (right to buy) exercised on 2026-08-06
Option exercise price
$179.66 per share
Conversion or exercise price for 4,179 options
Shares sold
4,179 shares
Common stock sale on 2026-08-06 following option exercise
Sale price
$259.16 per share
Per-share price for 4,179 common shares sold
Options expiration
2030-05-29
Expiration date of the exercised stock options
Derivative shares remaining from grant
0 shares
Total shares following transaction for this option position
Key Terms
Stock Options (Right to Buy), Exercise or conversion of derivative security, derivative
3 terms
Stock Options (Right to Buy) financial
"security_title: Stock Options (Right to Buy)"
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
derivative financial
"transaction_type: derivative"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CRL executive Victoria L. Creamer report?
Victoria L. Creamer reported exercising stock options for 4,179 shares of Charles River Laboratories common stock and selling 4,179 shares on 2026-08-06 in a same-day exercise-and-sell transaction.
How many CRL options did Victoria L. Creamer exercise in this Form 4 filing?
Victoria L. Creamer exercised stock options covering 4,179 shares of Charles River Laboratories common stock, originally exercisable at $179.66 per share, and then sold the same number of shares on the transaction date.
What is the expiration and grant exercise date of the CRL options exercised by Victoria L. Creamer?
The exercised Charles River Laboratories options had an exercise date of 2021-05-29 and an expiration date of 2030-05-29, and were fully exercised for 4,179 underlying shares in this transaction.
Does the Form 4 indicate remaining derivative positions for Victoria L. Creamer in this CRL option grant?
For this specific option grant, the Form 4 shows 0 derivative shares remaining after exercising 4,179 options. The derivative position tied to this grant was fully used in the reported exercise.
Was Victoria L. Creamer’s CRL stock sale reported as a planned 10b5-1 transaction?
The filing’s Rule 10b5-1 plan checkbox is not marked as affirming a trading plan, and no footnote indicates a 10b5-1 arrangement for these Charles River Laboratories transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates